Chapman, Nathaniel S.
Hulswit, Ruben J. G. http://orcid.org/0000-0001-7518-5538
Westover, Jonna L. B. http://orcid.org/0000-0002-3642-2980
Stass, Robert http://orcid.org/0000-0002-5224-0036
Paesen, Guido C. http://orcid.org/0000-0003-2373-2645
Binshtein, Elad http://orcid.org/0000-0003-2745-104X
Reidy, Joseph X.
Engdahl, Taylor B.
Handal, Laura S. http://orcid.org/0000-0001-8658-4411
Flores, Alejandra http://orcid.org/0000-0002-0857-424X
Gowen, Brian B. http://orcid.org/0000-0001-9113-2575
Bowden, Thomas A. http://orcid.org/0000-0002-8066-8785
Crowe, James E. Jr. http://orcid.org/0000-0002-0049-1079
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (HHSN272201700041I)
RCUK | Medical Research Council (MR/S007555/1)
Wellcome Trust (203141/Z/16/Z)
Article History
Received: 10 September 2022
Accepted: 22 August 2023
First Online: 13 September 2023
Competing interests
: J.E.C. has served as a consultant for Luna Innovations, Merck Sharp & Dohme, Emergent Biosolutions, and GlaxoSmithKline; is a member of the Scientific Advisory Board of Meissa Vaccines; a former member of the Scientific Advisory Board of Gigagen (Grifols); and is founder of IDBiologics. The laboratory of J.E.C. received unrelated sponsored research agreements from AstraZeneca, Takeda, and IDBiologics during the conduct of the study. Vanderbilt University has applied for patents for some of the antibodies in this paper (International Patent Application No. PCT/US2021/012720). The other authors declare no competing interests.